Myriad Genetics, Inc. (MYGN) News
Track canonical SquawkNews coverage tagged to MYGN, Myriad Genetics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Myriad Genetics Affirms FY2026 Sales Guidance of $770.000M-$790.000M vs $776.790M Est
Myriad Genetics (NASDAQ: MYGN ) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.
LIVE | Sep 16, 2026, 12:56 PM UTC
L
MYGN - Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
MYGN - Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
NEWS | Sep 16, 2026, 12:01 PM UTC
L
UBS keeps Myriad Genetics at neutral; price target cut
UBS maintains a neutral view on Myriad Genetics and cuts its price target to $3.60 per share from $6.00, according to Benzinga ratings actions.
EQUITY | Sep 09, 2026, 06:15 PM UTC
L
Myriad Genetics cut to underweight from overweight
Myriad Genetics was cut to underweight from overweight by Piper Sandler.
EQUITY | Sep 02, 2026, 09:14 AM UTC
M
Myriad Genetics shares fall 6.2% after Piper Sandler downgrade
Myriad Genetics shares fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, saying major strategic action is likely needed.
EQUITY | Sep 01, 2026, 06:41 PM UTC
L
This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse. — Barrons.com
By Mackenzie TatananniAs shares of Myriad Genetics show no signs of returning to their peak from over two decades ago, one firm double-downgraded the already depressed stock, saying the company's latest earnings cast dou
EARNINGS | Sep 01, 2026, 04:38 PM UTC
L
Myriad Genetics to present at 2026 Wells Fargo Healthcare conference
Myriad Genetics says it will present at the 2026 Wells Fargo Healthcare Conference.
EQUITY | Aug 27, 2026, 01:05 PM UTC
H
Crude Oil Gains 1%; Apple Shares Tumble After Q3 Results
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 200 points on Friday. The Dow traded up 0.38% to 52,406.69 while the NASDAQ rose 0.25% to 25,184.43. The S&P 500 also rose, gainin
EARNINGS | Jul 31, 2026, 04:02 PM UTC
H
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 300 points on Friday. Shares of Apple Inc (NASDAQ: AAPL ) fell sharply in pre-market trading after the company posted results for th
EARNINGS | Jul 31, 2026, 12:03 PM UTC
H
US Stocks Rise After Earnings
US stocks rise after earnings reports
EARNINGS | Jul 31, 2026, 11:56 AM UTC
H
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Amazon.com Inc (NASDAQ: AMZN ) rose sharply in pre-market trading after the company posted upbeat financial results for the second quarter. Amazon reported second-quarter revenue of $200.61 billion, beating the
EARNINGS | Jul 31, 2026, 08:50 AM UTC
L
Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know
Myriad Genetics Inc. (NASDAQ: MYGN ) shares plunged 37.80% in Thursday’s after-hours session after the company reported second-quarter 2026 financial results that included lower revenue, an operating loss, reduced full-y
EARNINGS | Jul 31, 2026, 05:48 AM UTC
L
MYGN Posts Wider Q2 Loss
MYGN reports wider Q2 loss
EARNINGS | Jul 30, 2026, 08:46 PM UTC
H
MYGN -29%, RBLX -11.6%, FLGT -10.7%, VCYT -9.8%, SYK -9.5%, ALHC -8.6%, COIN -6.5%, RDDT -5.8%, GSIT -5.3%, IR -3.1% after results
MYGN -29%, RBLX -11.6%, FLGT -10.7%, VCYT -9.8%, SYK -9.5%, ALHC -8.6%, COIN -6.5%, RDDT -5.8%, GSIT -5.3%, IR -3.1% after results
EARNINGS | Jul 30, 2026, 08:15 PM UTC
L
MYGN Myriad Genetics RESULTS: Q2, Q2 REV $190.7M vs. EST $206M, Q2 operating expenses $165.9M, Q2 ADJ operating expenses $150.5M, Q2 Operati
MYGN Myriad Genetics RESULTS: Q2, Q2 REV $190.7M vs. EST $206M, Q2 operating expenses $165.9M, Q2 ADJ operating expenses $150.5M, Q2 Operating Income $-38.9M, Q2 gross margin 66.6%
EARNINGS | Jul 30, 2026, 08:07 PM UTC
L
MYGN - Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Pro
MYGN - Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
EARNINGS | Jul 30, 2026, 08:06 PM UTC
L
Myriad Genetics Lowers FY2026 Sales Guidance from $860.000M-$880.000M to $770.000M-$790.000M vs $863.568M Est
Myriad Genetics (NASDAQ: MYGN ) lowers FY2026 sales outlook from $860.000 million-$880.000 million to $770.000 million-$790.000 million vs $863.568 million estimate.
EARNINGS | Jul 30, 2026, 08:06 PM UTC
M
MYGN Expands Cancer Test
Myriad Genetics expands availability of Precise MRD for colorectal, renal, and breast cancers
EQUITY | Jun 23, 2026, 01:05 PM UTC